Can 5-methyltetrahydrofolate modify the phospholipid fatty acid pattern in cystic fibrosis pediatric patients?

J Cyst Fibros. 2006 Aug;5(3):197-9. doi: 10.1016/j.jcf.2006.01.006. Epub 2006 Mar 3.

Abstract

Recent studies have reported an imbalance between n6 and n3 fatty acids (AA and DHA) in subjects with CF. Alterations in fatty acid amounts are present in CFTR-expressing tissues, plasma and in circulating blood cells. It has been reported that the correction of polyunsaturated fatty acid deficiency reversed the organ pathologies observed in CF knockout mice. We describe a CF child with an unusual clinical course presenting high molar percentage of DHA in plasma and red cells membrane during supplementation with 5-methyltetrahydrofolate and vitamin B12.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Chymotrypsin / analysis
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / metabolism*
  • Dietary Supplements
  • Docosahexaenoic Acids / blood
  • Docosahexaenoic Acids / metabolism*
  • Fatty Acids, Omega-6 / blood
  • Fatty Acids, Omega-6 / metabolism*
  • Female
  • Folic Acid / pharmacology*
  • Humans
  • Infant, Newborn
  • Methylation
  • Milk, Human / chemistry
  • Tetrahydrofolates / pharmacology*

Substances

  • Fatty Acids, Omega-6
  • Tetrahydrofolates
  • Docosahexaenoic Acids
  • Folic Acid
  • Chymotrypsin
  • 5-methyltetrahydrofolate